Ivonescimab is Now Being Studied in Europe in HARMONi-7 Trial – Lung Cancer Europe
Lung Cancer Europe shared a post on LinkedIn: “Ivonescimab was one of the most talked-about drugs in lung cancer at ASCO 2026, largely on the back of the HARMONi-6 results. […]
Read the full articleYou might also wanna read
ClinicalKey
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell #LungCancer (HARMONi-6): interim ove
clinicalkey.com·1mo agoLung Cancer Patients on Drug From China’s Akeso Lived Longer
Promising news announced #ASCO26 for patients with #lungcancer. Dr. Roy Herbst comments on ivonescimab, noting the initial study results fro
<![CDATA[HARMONi-6: Evaluating the Safety and Generalizability of Ivonescimab in NSCLC]]>
Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
Conditions : HNSCC; OSCC; OPSCC; Ivonescimab Interventions : Drug: Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） Sponsors : Zhujiang Ho
A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)
Conditions : Carcinoma, Non-Small-Cell Lung Sponsors : Janssen-Cilag Farmaceutica Ltda. Not yet recruiting
A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC
Conditions : NSCLC Interventions : Drug: SYS6010 Sponsors : Sichuan University Not yet recruiting
Comments
Sign in to join the conversation.
No comments yet. Be the first.